{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:16:06Z","timestamp":1790612166014,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An accurate prediction of cardiovascular (CV) risk in patients with Axial Spondyloarthritis (axSpA) is a strong unmet need, as CV risk algorithms poorly perform in these subjects. The aim of this study was to establish whether the persistence of high C-reactive protein (CRP) and high disease activity may be considered predictive factors of CVD in axSpA. 295 patients without personal history of CVD, were consecutively enrolled in this study. To evaluate the relationship between CV events occurrence (fatal and non-fatal) and the persistence of increased CRP levels, ASDAS (Ankylosing Spondylitis Disease Activity Score)\u2009&gt;\u20092.1, and BASDAI (Bath Ankylosing Spondylitis Disease Activity)\u2009&gt;\u20094 during the follow-up, univariable and multivariable Cox Proportional Hazard Models have been performed. During follow-up (we analyzed 10-years retrospective data), 23 patients had a CV event. Multivariable Cox Proportional Hazard Models showed a strong association between CV event and the persistency of increased CRP levels (namely, percentage of visits in which CRP levels were increased) (HR\u2009=\u20091.03; 95%CI 1.015\u20131.045; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), of ASDAS\u2009&gt;\u20092.1 (HR\u2009=\u20091.014, 95%CI 1.000\u20131.028, <jats:italic>p<\/jats:italic>\u2009=\u20090.047), and of BASDAI\u2009&gt;\u20094 (HR 1.019, 95%CI 1.006\u20131.033, <jats:italic>p<\/jats:italic>\u2009=\u20090.006) during follow-up, after adjustment for age, sex, and diabetes. This study suggests that persistence of increased CRP levels and high disease activity may be considered biomarkers to identify those axSpA patients at higher risk of CVD. Innovative axSpA-specific CV risk score, including these variables, have to be developed.<\/jats:p>","DOI":"10.1038\/s41598-022-11640-8","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T10:05:04Z","timestamp":1651917904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis"],"prefix":"10.1038","volume":"12","author":[{"given":"Luca","family":"Navarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Currado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Biaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Pavlych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Camarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"D\u2019Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Afeltra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,7]]},"reference":[{"issue":"1","key":"11640_CR1","first-page":"1","volume":"11","author":"J Sieper","year":"2015","unstructured":"Sieper, J., Braun, J., Dougados, M. & Baeten, D. Axial spondyloarthritis. Nat. Rev. Dis. Prim. 11(1), 1\u201316 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"11640_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102648","volume":"19","author":"MS Chimenti","year":"2020","unstructured":"Chimenti, M. S. et al. Tackling the autoimmune side in Spondyloarthritis: A systematic review. Autoimmun. Rev. 19, 102648 (2020).","journal-title":"Autoimmun. Rev."},{"key":"11640_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Van Der Heijde","year":"2017","unstructured":"Van Der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76, 978\u2013991 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"11640_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/msc.1513","volume":"19","author":"K Kelly","year":"2021","unstructured":"Kelly, K. Ankylosing spondylitis and undifferentiated spondyloarthritis: The relationship between living with these diseases and psychological well-being. Musculoskeletal Care 19, 158\u2013164 (2021).","journal-title":"Musculoskeletal Care"},{"key":"11640_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s11136-020-02686-0","volume":"30","author":"B Hoepken","year":"2021","unstructured":"Hoepken, B., Serrano, D., Harris, K., Hwang, M. C. & Reveille, J. Validation of the ankylosing spondylitis quality of life assessment tool in patients with non-radiographic axial spondyloarthritis. Qual. Life Res. 30, 945\u2013954 (2021).","journal-title":"Qual. Life Res."},{"key":"11640_CR6","doi-asserted-by":"crossref","unstructured":"Ruscitti, P. et al. Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study. PLoS One 12, (2017).","DOI":"10.1371\/journal.pone.0170108"},{"key":"11640_CR7","doi-asserted-by":"crossref","unstructured":"Romano, S. et al. Cardiovascular and metabolic comorbidities in rheumatoid arthritis. Curr. Rheumatol. Rep. 20, (2018).","DOI":"10.1007\/s11926-018-0790-9"},{"key":"11640_CR8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3899\/jrheum.170534","volume":"44","author":"L Eder","year":"2017","unstructured":"Eder, L. & Harvey, P. Cardiovascular morbidity in psoriatic arthritis: What is the effect of inflammation?. J. Rheumatol. 44, 1295\u20131297 (2017).","journal-title":"J. Rheumatol."},{"key":"11640_CR9","doi-asserted-by":"crossref","unstructured":"England, B. R., Thiele, G. M., Anderson, D. R. & Mikuls, T. R. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. BMJ 361, (2018).","DOI":"10.1136\/bmj.k1036"},{"key":"11640_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04458-7","author":"F Caso","year":"2019","unstructured":"Caso, F. et al. Mediterranean diet and Psoriatic Arthritis activity: A multicenter cross-sectional study. Rheumatol. Int. https:\/\/doi.org\/10.1007\/s00296-019-04458-7 (2019).","journal-title":"Rheumatol. Int."},{"key":"11640_CR11","first-page":"487","volume":"12","author":"L Navarini","year":"2020","unstructured":"Navarini, L. et al. Experimental and investigational pharmacotherapy for psoriatic arthritis: Drugs of the future. J. Exp. Pharmacol. 12, 487\u2013502 (2020).","journal-title":"J. Exp. Pharmacol."},{"key":"11640_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2016","unstructured":"Agca, R. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann. Rheum. Dis. 76, 17\u201328 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"11640_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.mcna.2017.03.002","volume":"101","author":"MJ Pletcher","year":"2017","unstructured":"Pletcher, M. J. & Moran, A. E. Cardiovascular risk assessment. Med. Clin. North Am. 101, 673\u2013688 (2017).","journal-title":"Med. Clin. North Am."},{"key":"11640_CR14","doi-asserted-by":"crossref","unstructured":"Ruscitti, P. et al. Subclinical and clinical atherosclerosis in rheumatoid arthritis: Results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Res. Ther. 21, (2019).","DOI":"10.1186\/s13075-019-1975-y"},{"key":"11640_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/annrheumdis-2014-206879","volume":"75","author":"EEA Arts","year":"2016","unstructured":"Arts, E. E. A. et al. Prediction of cardiovascular risk in rheumatoid arthritis: Performance of original and adapted SCORE algorithms. Ann. Rheum. Dis. 75, 674\u2013680 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"11640_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino, R. B. et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation 117, 743\u2013753 (2008).","journal-title":"Circulation"},{"key":"11640_CR17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","volume":"336","author":"J Hippisley-Cox","year":"2008","unstructured":"Hippisley-Cox, J. et al. Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of QRISK2. BMJ 336, 1475\u20131482 (2008).","journal-title":"BMJ"},{"key":"11640_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00233-4","author":"L Navarini","year":"2020","unstructured":"Navarini, L. et al. Cardiovascular risk prediction in ankylosing spondylitis: From traditional scores to machine learning assessment. Rheumatol. Ther. https:\/\/doi.org\/10.1007\/s40744-020-00233-4 (2020).","journal-title":"Rheumatol. Ther."},{"key":"11640_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez677","author":"L Navarini","year":"2020","unstructured":"Navarini, L. et al. A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis. Rheumatology (Oxford) https:\/\/doi.org\/10.1093\/rheumatology\/kez677 (2020).","journal-title":"Rheumatology (Oxford)"},{"key":"11640_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14451","author":"C Conforti","year":"2020","unstructured":"Conforti, C. et al. Moderate-to-severe plaque psoriasis, described by PASI \u226510%, can be associated with higher cardiovascular risk according to seven risk algorithms: Results of a 10-year single-center retrospective study and clinical management of psoriatic patients with ca. Dermatol. Ther. https:\/\/doi.org\/10.1111\/dth.14451 (2020).","journal-title":"Dermatol. Ther."},{"issue":"Suppl 11","key":"11640_CR21","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling, J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), bath ankylosing spondylitis disease activity index (BASDAI), bath ankylosing spondylitis functional index (BASFI), bath ankylosing spondylitis global score (BAS-G), bath ankylosing spondylitis metrology index (BASMI), dougados functional index (DFI), and health assessment questionnaire for the spondylarthropathies (HAQ-S). Arthritis Care Res. (Hoboken) 63(Suppl 11), S47\u2013S58 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"11640_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.trsl.2015.05.006","volume":"167","author":"J Shen","year":"2016","unstructured":"Shen, J., Shang, Q. & Tam, L. S. Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. Transl. Res. 167, 138\u2013151 (2016).","journal-title":"Transl. Res."},{"key":"11640_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1570161118666200721145718","volume":"18","author":"AS Manolis","year":"2020","unstructured":"Manolis, A. S. & Tzioufas, A. G. Cardio-rheumatology: Two collaborating disciplines to deal with the enhanced cardiovascular risk in autoimmune rheumatic diseases. Curr. Vasc. Pharmacol. 18, 533\u2013537 (2020).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"11640_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/1744666X.2020.1740593","volume":"16","author":"F Caso","year":"2020","unstructured":"Caso, F. et al. Metabolic syndrome and psoriatic arthritis: Considerations for the clinician. Expert Rev. Clin. Immunol. 16, 409\u2013420 (2020).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"11640_CR25","first-page":"143","volume":"11","author":"R Peluso","year":"2019","unstructured":"Peluso, R. et al. Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. Open Access Rheumatol. Res. Rev. 11, 143\u2013156 (2019).","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"11640_CR26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00296-020-04616-2","volume":"40","author":"AI Venetsanopoulou","year":"2020","unstructured":"Venetsanopoulou, A. I., Pelechas, E., Voulgari, P. V. & Drosos, A. A. The lipid paradox in rheumatoid arthritis: The dark horse of the augmented cardiovascular risk. Rheumatol. Int. 40, 1181\u20131191 (2020).","journal-title":"Rheumatol. Int."},{"key":"11640_CR27","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/annrheumdis-2013-204636","volume":"74","author":"S Rollefstad","year":"2015","unstructured":"Rollefstad, S. et al. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention. Ann. Rheum. Dis. 74, 1544\u20131550 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"11640_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann. Rheum. Dis. 68, 777\u2013783 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"11640_CR29","doi-asserted-by":"crossref","unstructured":"Hippisley-Cox, J., Coupland, C. & Brindle, P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ 357, (2017).","DOI":"10.1136\/bmj.j2099"},{"key":"11640_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/2047487312443485","volume":"21","author":"I Van Dis","year":"2014","unstructured":"Van Dis, I. et al. Effect of including nonfatal events in cardiovascular risk estimation, illustrated with data from the Netherlands. Eur. J. Prev. Cardiol. 21, 377\u2013383 (2014).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"11640_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy, R. M. et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur. Heart J. 24, 987\u20131003 (2003).","journal-title":"Eur. Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11640-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:02:32Z","timestamp":1669345352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11640-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11640"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11640-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,7]]},"assertion":[{"value":"23 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7498"}}